Role of miRNA for the opioid tolerance in cancer pain treatment

• Project/Area Number: 23592318
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Anesthesiology/Resuscitation studies
• Research Institution: National Center of Neurology and Psychiatry
• Principal Investigator: SHIRAISHI Seiji 独立行政法人国立がん研究センター, 研究所, ユニット長 (90216177)
• Co-Investigator(Renkei-kenkyūsha): MORITA Katuya 広島大学, 歯科薬理学, 准教授 (10116684)
• Project Period (FY): 2011 – 2013
• Project Status: Completed (Fiscal Year 2013)
• Budget Amount: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000); Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2011: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
• Keywords: 癌 / miRNA / モルヒネ / がん性疼痛

Research Abstract

A purpose of this study was to determined the relation of the opioid tolerance and the changes of miRNA in cancer pain treatment. We established a breast cancer bone pain model rat and analyzed the changes of miRNA using miRNA array kit. Hyperalgesia and allodynia symptom significantly occurred after breast cancer cells transplant from one week. We sampled two weeks after transplant and measured miRNA. 56 miRNA increased more than double as compared with the control and 9 miRNA decreased in less than half. We examined the effects of let-7 among this abnormal miRNA on the activity of u-opioid receptor stimulated by DAMGO and on expression of u-opioid receptor on cell surface membrane. However there was much unevenness and did not lead to constant results. miR-20a, miR-21, miR-23b, miR133a, and miR-133b were included in other abnormal miRNA.